抗凝药利伐沙班主要通过失活肝星状细胞降低肝硬化大鼠的门静脉高压
该研究在四氯化碳(CCl4)和硫代乙酰胺诱导的肝硬化大鼠中,给予利伐沙班(RVXB)20 mg/kg/天或溶媒治疗2周,评估肝脏与全身血流动力学、一氧化氮(NO)生物利用度、肝纤维化、肝星状细胞(HSC)活化及微血栓形成。结果显示RVXB显著降低两种模型的門静脉压力(PP),且不改变门静脉血流,提示肝内血管阻力(IHVR)下降;RVXB减少氧化应激、改善NO生物利用度和内皮功能障碍、使HSC失活、减少纤维蛋白沉积,但肝纤维化无显著变化。作者认为RVXB值得进一步评估作为肝硬化门静脉高压的潜在治疗。
要点
- 利伐沙班20 mg/kg/天治疗2周显著降低两种肝硬化大鼠模型的門静脉压力,不改变门静脉血流。
- 利伐沙班使肝星状细胞失活,减少α-平滑肌肌动蛋白及其他HSC活化标志物mRNA表达。
- 利伐沙班减少肝内纤维蛋白沉积,提示肝内微血栓形成减少,但肝纤维化无显著变化。
核心结论
- 利伐沙班降低两种肝硬化大鼠模型的門静脉压力,该效应主要与肝内血管阻力下降、NO生物利用度提高、HSC失活及肝内微血栓形成减少相关。
- 作者认为利伐沙班值得进一步评估作为肝硬化门静脉高压的潜在治疗。
研究设计与样本
- 研究在四氯化碳(CCl4)和硫代乙酰胺诱导的肝硬化大鼠中,给予利伐沙班(20 mg/kg/天)或溶媒治疗2周。
- 评估指标包括肝脏与全身血流动力学、NO生物利用度、肝纤维化、HSC活化及微血栓形成。
主要发现
- 利伐沙班显著降低两种肝硬化模型的門静脉压力,且不改变门静脉血流,提示肝内血管阻力下降。
- 利伐沙班减少氧化应激、改善NO生物利用度并改善内皮功能障碍。
- 利伐沙班使HSC失活,表现为α-平滑肌肌动蛋白及其他HSC活化标志物mRNA表达下降。
- 尽管HSC表型明显改善,肝纤维化未见显著变化。
- 利伐沙班显著减少纤维蛋白沉积,提示肝内微血栓形成减少。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary factor for portal hypertension (PH) development. Hepatic stellate cells (HSCs) play a major role increasing IHVR because, when activated, they are contractile and promote fibrogenesis. Protease-activated receptors (PARs) can activate HSCs through thrombin and factor Xa, which are known PAR agonists, and cause microthrombosis in liver microcirculation. This study investigates the effects of the oral anticoagulant, rivaroxaban (RVXB), a direct antifactor Xa, on HSC phenotype, liver fibrosis (LF), liver microthrombosis, and PH in cirrhotic rats. Hepatic and systemic hemodynamic, nitric oxide (NO) bioavailability, LF, HSC activation, and microthrombosis were evaluated in CCl4 and thioacetamide-cirrhotic rats treated with RVXB (20 mg/kg/day) or its vehicle for 2 weeks. RVXB significantly decreased portal pressure (PP) in both models of cirrhosis without changes in portal blood flow, suggesting a reduction in IHVR. RVXB reduced oxidative stress, improved NO bioavailability, and ameliorated endothelial dysfunction. Rivaroxaban deactivated HSC, with decreased alpha-smooth muscle actin and mRNA expression of other HSC activation markers. Despite this marked improvement in HSC phenotype, no significant changes in LF were identified. RVXB markedly reduced fibrin deposition, suggesting reduced intrahepatic microthrombosis. CONCLUSION: RVXB decreases PP in two rat models of cirrhosis. This effect is mostly associated with decreased IHVR, enhanced NO bioavailability, HSC deactivation, and reduced intrahepatic microthrombosis. Our findings suggest that RVXB deserves further evaluation as a potential treatment for cirrhotic PH. (Hepatology 2017;65:2031-2044).
引用
- Vilaseca M, García-Calderó H, Lafoz E, et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology. 2017. PMID: 28142199. doi:10.1002/hep.29084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。